Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7452895 | SEAGEN | Quinazoline analogs as receptor tyrosine kinase inhibitors |
Nov, 2024
(6 months from now) | |
US8648087 | SEAGEN | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
Apr, 2031
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9693989 | SEAGEN | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
May, 2027
(3 years from now) | |
US9457093 | SEAGEN | Solid dispersions of a ERB2 (HER2) inhibitor |
Oct, 2032
(8 years from now) | |
US11504370 | SEAGEN | Treatment of brain cancer |
Mar, 2033
(8 years from now) | |
US11207324 | SEAGEN | Treatment of HER2 positive cancers |
Apr, 2038
(14 years from now) |
Tukysa is owned by Seagen.
Tukysa contains Tucatinib.
Tukysa has a total of 6 drug patents out of which 0 drug patents have expired.
Tukysa was authorised for market use on 17 April, 2020.
Tukysa is available in tablet;oral dosage forms.
Tukysa can be used as treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer, combination treatment of colorectal cancer including ras wild-type her2 (erbb2)-positive or -overexpressing unresectable or metastatic colorectal cancer.
Drug patent challenges can be filed against Tukysa from 17 April, 2024.
The generics of Tukysa are possible to be released after 27 April, 2038.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-309) | Apr 17, 2027 |
New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
New Indication(I-906) | Jan 19, 2026 |
Orphan Drug Exclusivity(ODE-422) | Jan 19, 2030 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer; Combination treatment of colorectal cancer including ras wild-type her2 (erbb2)-positive or -overexpressing...
Dosage: TABLET;ORAL